相关实验视频
Updated: Sep 14, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
与代谢功能障碍相关的脂肪性肝病的抗纤维性疗法
Robert F Schwabe1,2,3,4,5, Frank Tacke5, Atsushi Sugimoto1
1Department of Medicine, Columbia University, New York, NY, USA.
与代谢功能障碍相关的脂肪性肝病 (MASLD) 治疗正在推进,新的疗法针对纤维化回归. 研究重点是将策略结合起来,以便在代谢功能障碍相关的脂肪肝炎 (MASH) 中获得更广泛的患者益处.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 纤维化研究 纤维化研究
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 影响全球超过25%的成年人.
- MASLD可以发展为与代谢功能障碍相关的脂肪肝炎 (MASH),增加肝纤维化,肝硬化和心血管问题的风险.
- 由细胞交叉声驱动的肝纤维化是MASLD结果的关键因素.
研究的目的:
- 审查目前和新的治疗策略,以减少MASLD和MASH中的肝纤维化.
- 讨论肝纤维化不同阶段新兴疗法的潜力.
- 突出需要特定阶段和组合疗法的需要.
主要方法:
- 对有关MASLD和MASH疗法的现有文献的审查.
- 对肝细胞和代谢向剂的临床试验数据的分析.
- 探索新的治疗概念,包括直接抗纤维素药物和基于细胞的疗法.
主要成果:
- 肝细胞和代谢向疗法已显示MASH患者的纤维化减少,导致FDA批准.
- 目前的治疗方法有利于一小部分患者,并且仅限于早期纤维化阶段 (F2-F3).
- 直接抗纤维素和基于巨细胞的疗法正在开发中,用于先进的MASH.
结论:
- 纤维化回归是MASH的关键治疗目标.
- 像巨细胞移植和CAR T细胞这样的新疗法正在扩大治疗选择.
- 整合不同的治疗方法对于改善MASH患者纤维化减少率至关重要.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Atherosclerosis III: Management
Chronic Pancreatitis II: Collaborative Care
Assessment:
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...